About us
Genbioma is a
pioneering company in the nutraceutical industry, dedicated to revolutionizing
the market with innovative microbiome-based ingredients aimed at metabolic
syndrome management. Established in 2019 and headquartered in Spain, Genbioma
has quickly positioned itself as a leader in the field, thanks to its
cutting-edge research and development efforts.
Our flagship
product, the postbiotic pA1c®HI, represents a significant breakthrough in the
management of glucose levels for prediabetic and diabetic people. Extensive
preclinical studies have been conducted to determine its mechanism of action
through the modulation of the gut microbiota. Additionally, pA1c®HI has been
clinically validated in an initial pilot trial, with several larger clinical
trials currently underway. One of the key
advantages of pA1c®HI is its stability and versatility. Unlike probiotic
products, pA1c®HI does not require a cold chain for storage and transportation,
making it highly convenient and cost-effective. This stability also allows it
to be included in various food processing applications, even those involving
heat, without losing its efficacy. The industrial-scale production of pA1c®HI is cost-effective, with a stability of three years under any thermal condition
Genbioma's value
proposition is built on a scalable business model that ensures safety,
effectiveness, and affordability. Our products comply with EFSA QPS and FDA
GRAS standards, making them safe for consumption. At Genbioma, we are
dedicated to improving health and wellness through scientifically validated
products that offer real benefits to consumers. Our team of experts continues
to push the boundaries of research and development, ensuring that we remain at
the forefront of the nutraceutical industry.
Specs about this supplier
| Sales markets | Asia; Eastern Europe; Middle East; Western Europe |
|---|---|
| Affiliated categories: | Glucose |Other Microorganisms & Probiotics |Biotic products More |